Drugs /

eftilagimod alpha

Back to Drugs List

Overview

NCI Definition [1]:
A T-cell immunostimulatory factor, derived from the soluble form of the lymphocyte-activation gene 3 (LAG-3) protein, with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, IMP321 binds with high affinity to MHC class II molecules expressed by dendritic cells (DC), potentially resulting in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses.

Clinical Trials

View Clinical Trials for eftilagimod alpha

Eftilagimod alpha has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating eftilagimod alpha, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).

ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for eftilagimod alpha clinical trials.

Breast adenocarcinoma, breast carcinoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in eftilagimod alpha clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Eftilagimod Alpha
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating eftilagimod alpha and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hlag-31g, immufact, immufact, imp321, efti, imp-321, eoc-202, edp-202, immufact-imp321, immufact imp321, slag-3-ig, lag-3-ig-fusion protein, lag-3ig
Drug Target(s) [2]:
HLA-DPA1, HLA-DPA3, HLA-DPB1, HLA-DPB2, HLA-DQA1, HLA-DRA, HLA-DRB1, HLA-DRB6
NCIT ID [1]:
C62509

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.